Mylan Pharmaceuticals Inc. and Sandoz have reached agreements with Vifor Pharma Group and its partner American Regent regarding patent litigation brought in response to abbreviated new drug applications to market generic versions of Injectafer (ferric carboxymaltose) in the US.
Viatris And Sandoz May Market Injectafer Generic In US From 2026
ANDA Disputes Regarding Ferric Carboxymaltose Are Now Settled
After over two years of litigation, Vifor and American Regent have reached agreements with Viatris’ Mylan and Sandoz regarding their generic ferric carboxymaltose products, allowing both companies to bring rivals to market ahead of the expiry of certain US patents.
